April 4, 2016
(Bloomberg) – GlaxoSmithKline Plc won the backing of the European Union’s drug regulator for its first gene therapy, which treats a rare disease that makes newborn babies unable to fight off everyday infections. The therapy, which will be marketed as Strimvelis, was recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, the London-based drugmaker said Friday in a statement. The European Commission usually follows the committee’s advice.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.